Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Information Request
Investor FAQs
Get News Alerts by Email
All RSS Feeds
Get News Alerts by Email
* Required Fields
(Click here to unsubscribe)
All Alerts
Customize Alerts
All Events
CEO Panel Discussion
Financial Conferences
Medical Conference
Results Announcements
Scientific Conference
Stockholder Meetings
Webcasts
Daily Closing Stock Price
Stock Price: End of Week Summary
All SEC Filings
Annual Filings
Quarterly Filings
Current Filings
Registration Statements
Section 16
Mergers & Acquisitions
Proxy & Information Statements
Other
Press Releases
Stories
First Name
Last Name
* Email
Company
Phone